Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells.

Abstract

We have previously shown that ML-7, which inhibits myosin light chain kinase (MLCK), induces apoptosis in transformed and non-transformed cells. We have extended these studies and found that ML-7 stimulates the ability of etoposide to induce apoptosis in Mm5MT mouse mammary adenocarcinoma cells and Mat-Ly-Lu rat prostate cancer cells in vitro. ML-7 was also found to have a chemopreventive effect using an in vitro mouse mammary organ culture model. In vivo experiments demonstrated that ML-7 retards the growth of mammary tumours in mice and prostate tumours in rats. Moreover, ML-7 significantly stimulates the ability of etoposide to prevent the growth of established mammary tumours in mice and prostate tumours in rats. These results provide evidence for the efficacy of ML-7 as an adjuvant to etoposide in these models and warrants further development.

• Authors: Lian-Zhi Gu, Wen-Yang Hu, Nenad Antic, Rajendra Mehta, Jerrold R Turner, Primal de Lanerolle
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 42 Issue 7 Pg. 948-57 (May 2006) ISSN: 0959-8049 [Print] England
• PMID: 16574402 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antineoplastic Agents, Phytogenic
• Azepines
• Naphthalenes
• ML 7
• Etoposide
• Myosin-Light-Chain Kinase

Topics

• Adenocarcinoma (drug therapy, pathology)
• Animals
• Antineoplastic Agents, Phytogenic (therapeutic use)
• Apoptosis (drug effects)
• Azepines (pharmacology)
• Cell Division
• Chemotherapy, Adjuvant
• Etoposide (therapeutic use)
• Humans
• Male
• Mammary Neoplasms, Experimental (drug therapy, pathology)
• Mice
• Mice, Inbred BALB C
• Myosin-Light-Chain Kinase (antagonists & inhibitors)
• Naphthalenes (pharmacology)
• Prostatic Neoplasms (drug therapy, pathology)
• Random Allocation
• Rats